NYMOX REPORTS POSITIVE RESULTS FOR 2 YEAR NX-1207 BPH STUDY

摘要

Nymox Pharmaceutical Corporation (NASDAQ:NYMX),Hasbrouck,Heights,N.J.,has announced positive results from a newly-completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH).24 clinical trial sites across the U.S.and 103 unselected subjects participated in the blinded,placebo controlled study.